| Literature DB >> 35498029 |
Ming-Jer Hsieh1,2, Chun-Chi Chen1,2, Dong-Yi Chen1,2, Cheng-Hung Lee1,2, Ming-Yun Ho1,2, Jih-Kai Yeh1,2, Yu-Chang Huang1,2, Yu-Ying Lu1,2, Chieh-Yu Chang1,2, Chao-Yung Wang1,2, Shang-Hung Chang1,2,3, I-Chang Hsieh1,2.
Abstract
Background: Coronary perfusion pressure (CPP) and coronary artery stenosis are responsible for myocardial perfusion. However, how CPP-related survival outcome affects revascularization is unclear. Objective: The aim of this study is to investigate the prognostic role of CPP in patients with left ventricular systolic dysfunction (LVSD) undergoing percutaneous coronary intervention (PCI) with complete revascularization (CR) or reasonable incomplete revascularization (RIR).Entities:
Keywords: complete revascularization; coronary perfusion pressure; left ventricular systolic dysfunction; reasonable incomplete revascularization; residual SYNTAX score
Year: 2022 PMID: 35498029 PMCID: PMC9046789 DOI: 10.3389/fcvm.2022.860346
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Flowchart of patient enrolment. CPP, coronary perfusion pressure; CR, complete revascularisation; RIR, reasonable incomplete revascularisation; rSS, residual SYNTAX score.
Baseline characteristics of patients with left ventricular systolic dysfunction (LVSD) according to the tertile of coronary perfusion pressure.
|
| ||||
|---|---|---|---|---|
| Patient number, | 297 | 264 | 255 | |
| Age, years | 65.6 ± 11.7 | 62.0 ± 11.7 | 61.8 ± 11.5 | <0.001 |
| Female gender, | 60 (20.2) | 53 (20.1) | 48 (18.8) | 0.908 |
| Diabetes mellitus, | 122 (41.1) | 115 (43.6) | 87 (34.1) | 0.074 |
| Hypertension, | 139 (46.8) | 149 (56.4) | 155 (60.8) | 0.003 |
| Hyperlipidemia, | 139 (46.8) | 148 (56.1) | 123 (48.2) | 0.067 |
| Smoking, | 133 (44.8) | 111 (42.0) | 112 (43.9) | 0.803 |
| CKD ≥3, | 59 (19.9) | 45 (17.0) | 21 (8.2) | <0.001 |
| Previous stroke, | 14 (4.7) | 18 (6.8) | 9 (3.5) | 0.219 |
| NYHA Fc ≥3, | 73 (24.6) | 63 (23.9) | 40 (15.7) | 0.022 |
| LVEF, % | 34.6 ± 7.8 | 34.9 ± 8.0 | 35.4 ± 7.8 | 0.514 |
| LVEF <35%, | 139 (46.8) | 117 (44.3) | 106 (41.6) | 0.467 |
| Calcified lesions, | 74 (24.9) | 62 (23.5) | 54 (21.2) | 0.582 |
| Chronic total occlusion, | 27 (9.1) | 23 (8.3) | 36 (14.1) | 0.089 |
| SBP, mmHg | 129.8 ± 24.9 | 138.3 ± 24.9 | 150.4 ± 23.6 | <0.001 |
| DBP, mmHg | 63.8 ± 10.0 | 73.3 ± 8.2 | 85.9 ± 12.2 | <0.001 |
| Heart rate, beat/min | 72.3 ± 12.0 | 75.1 ± 14.6 | 75.8 ± 13.9 | 0.005 |
| LVEDP, mmHg | 29.4 ± 8.3 | 24.7 ± 8.0 | 20.5 ± 9.1 | <0.001 |
| rSS, mean | 2.2 ± 3.2 | 2.1 ± 3.1 | 2.2 ± 3.1 | 0.862 |
| RIR (rSS: 5 to 8), | 84 (28.3) | 68 (25.8) | 65 (25.5) | 0.709 |
| RIR (rSS: 1 to 4), | 24 (8.1) | 24 (9.1) | 25 (9.8) | 0.775 |
| CR (rSS = 0), | 189 (63.6) | 172 (65.2) | 164 (64.3) | 0.932 |
| ACEi or ARB, | 242 (81.5) | 219 (83.0) | 219 (85.9) | 0.377 |
| Beta-blocker, | 262 (88.2) | 235 (89.0) | 233 (91.4) | 0.465 |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; CPP, coronary perfusion pressure; CR, complete revascularization; DBP, diastolic blood pressure; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; NYHA Fc, New York Heart Association functional class; RIR, reasonable incomplete revascularization; rSS, residual SYNTAX score; SBP, systolic blood pressure.
Incidence and risk of mortality according to the tertile of coronary perfusion pressure (CPP).
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Highest (≥55) | 255 | 34 (13.3) | 28.7 | 1.00 [Reference] | – | 1.00 [Reference] | – |
| Intermediate (43–54) | 264 | 35 (13.3) | 28.6 | 1.00 (0.62–1.60) | 0.998 | 0.94 (0.58–1.52) | 0.798 |
| Lowest ( ≤ 42) | 297 | 65 (21.9) | 49.7 | 1.73 (1.14–2.62) | 0.010 | 1.63 (1.06–2.49) | 0.026 |
CI, confidence interval; CPP, coronary perfusion pressure.
Adjusted for clinical variables including age (per 10 years), gender, hypertension, diabetes mellitus, hyperlipidemia, smoking, previous stroke, chronic kidney disease, NYHA Fc ≥3, left ventricular ejection fraction <35%, calcified lesions, systolic blood pressure, heart rate, complete revascularization, use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and beta-blockers in a Cox proportional regression model.
Baseline characteristics of matched population according to CPP and revascularization status.
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
| Age, years old | 67.2 ± 11.6 | 67.6 ± 10.7 | 66.9 ± 12.6 | 0.639 | 62.2 ± 11.5 | 62.0 ± 11.3 | 62.4 ± 11.7 | 0.773 | <0.001 |
| Female gender, | 42 (20.8) | 23 (22.8) | 19 (18.8) | 0.603 | 79 (22.6) | 39 (22.3) | 40 (22.9) | 1.000 | 0.670 |
| Diabetes mellitus, | 96 (47.5) | 47 (46.5) | 49 (48.5) | 0.888 | 162 (46.3) | 83 (47.4) | 79 (45.1) | 0.748 | 0.791 |
| Hypertension, | 107 (53.0) | 54 (53.5) | 53 (52.5) | 1.000 | 240 (68.6) | 119 (68.0) | 121 (69.1) | 0.908 | <0.001 |
| Hyperlipidaemia, | 96 (47.5) | 51 (50.5) | 45 (44.6) | 0.481 | 175 (50.0) | 97 (55.4) | 78 (44.6) | 0.054 | 0.597 |
| Smoking, | 89 (44.1) | 45 (44.6) | 44 (43.6) | 1.000 | 133 (38.0) | 75 (42.9) | 58 (33.1) | 0.078 | 0.177 |
| CKD stage ≥3, | 42 (20.8) | 20 (19.8) | 22 (21.8) | 0.863 | 55 (15.7) | 28 (16.0) | 27 (15.4) | 1.000 | 0.133 |
| Previous stroke, | 12 (5.9) | 7 (6.9) | 5 (5.0) | 0.767 | 16 (4.6) | 9 (5.1) | 7 (4.0) | 0.799 | 0.547 |
| NYHA Fc ≥3, | 56 (27.7) | 30 (29.7) | 26 (25.7) | 0.637 | 76 (21.7) | 42 (24.0) | 34 (19.4) | 0.364 | 0.121 |
| LVEF, % | 34.0 ± 8.0 | 34.0 ± 8.2 | 34.0 ± 7.9 | 0.986 | 34.4 ± 8.3 | 34.6 ± 8.4 | 34.3 ± 8.3 | 0.798 | 0.518 |
| LVEF <35, | 97 (48.0) | 50 (49.5) | 47 (46.5) | 0.778 | 164 (46.9) | 81 (46.3) | 83 (47.4) | 0.915 | 0.860 |
| Calcified lesion, | 55 (27.2) | 28 (27.7) | 27 (26.7) | 1.000 | 83 (23.7) | 45 (25.7) | 38 (21.7) | 0.451 | 0.361 |
| Chronic total occlusion, | 18 (8.9) | 7 (6.9) | 11 (10.9) | 0.460 | 40 (11.4) | 17 (9.7) | 23 (13.1) | 0.401 | 0.390 |
| ACEi or ARB, | 166 (82.2) | 84 (83.2) | 82 (81.2) | 0.854 | 295 (84.3) | 145 (82.9) | 150 (85.7) | 0.557 | 0.552 |
| Beta-blocker, | 178 (88.1) | 88 (87.1) | 90 (89.1) | 0.828 | 316 (90.3) | 159 (90.9) | 157 (89.7) | 0.857 | 0.472 |
| SBP, mmHg | 131.2 ± 24.8 | 132.3 ± 26.4 | 130.1 ± 23.3 | 0.531 | 144.9 ± 25.1 | 145.6 ± 24.7 | 144.3 ± 25.5 | 0.639 | <0.001 |
| DBP, mmHg | 63.3 ± 10.0 | 62.5 ± 9.9 | 64.2 ± 10.1 | 0.217 | 79.1 ± 11.5 | 79.1 ± 11.0 | 79.1 ± 12.0 | 0.974 | <0.001 |
| Heart rate, beat/min | 72.3 ± 12.1 | 73.0 ± 12.3 | 71.6 ± 11.9 | 0.410 | 75.9 ± 14.1 | 75.4 ± 13.8 | 76.4 ± 14.4 | 0.492 | 0.003 |
| LVEDP, mmHg | 29.4 ± 8.6 | 28.4 ± 9.1 | 30.5 ± 8.0 | 0.086 | 22.4 ± 9.1 | 21.9 ± 9.6 | 22.8 ± 8.5 | 0.359 | <0.001 |
| CPP, mmHg | 33.9 ± 8.0 | 34.1 ± 6.1 | 33.7 ± 8.0 | 0.744 | 56.8 ± 11.0 | 57.2 ± 10.9 | 56.3 ± 11.2 | 0.431 | <0.001 |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; CPP, coronary perfusion pressure; DBP, diastolic blood pressure; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; NYHA Fc, New York Heart Association functional class; SBP, systolic blood pressure.
Incidence and risk of long-term mortality between subgroups.
|
|
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| ||
| >42 | CR | 336 | 38 | 11.3 | 175 | 24 | 13.7 | 1.00 [Reference] | – | 1.00 [Reference] | – |
| RIR | 183 | 31 | 16.9 | 175 | 28 | 16.0 | 1.20 (0.70–2.07) | 0.513 | 1.11 (0.65–1.93) | 0.695 | |
| ≤ 42 | CR | 189 | 33 | 17.5 | 101 | 14 | 13.9 | 1.00 [Reference] | – | 0.99 (0.51–1.91) | 0.965 |
| RIR | 108 | 32 | 29.6 | 101 | 30 | 29.7 | 2.39 (1.27–4.50) | 0.007 | 2.12 (1.23–3.66) | 0.007 | |
CI, confidence interval; CPP, coronary perfusion pressure; CR, complete revascularisation; HR, hazards ratio; PCI, percutaneous coronary interventions; RIR, reasonable incomplete revascularisation.
Figure 2Kaplan–Meier curves and relative risks for all-cause mortality in four subgroups. Patients in propensity-matched population were divided into four subgroups according to CPP (>42 or ≤ 42 mmHg) and revascularisation strategy (RIR or CR). The relative risks of mortality between the four subgroups were adjusted in Cox-proportional hazards analysis. CPP, coronary perfusion pressure; CR, complete revascularisation; RIR, reasonable incomplete revascularisation; * means p < 0.05.
Figure 3Schematic representation of the implication of coronary perfusion pressure (CPP) for revascularisation strategy selection in patients with left ventricular systolic dysfunction (LVSD) undergoing percutaneous coronary intervention (PCI). CPP, coronary perfusion pressure; LVSD, left ventricular systolic dysfunction; PCI, percutaneous coronary intervention.